Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies

NCT04277637 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT04277637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04277637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 24, 2020
Completion date
May 31, 2027
Enrollment
437 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

mature b-cell malignancies